A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Volasertib (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 03 May 2018 Planned End Date changed from 1 Sep 2022 to 1 Feb 2017.
- 03 May 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2017.
- 15 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.